Have we reached the point of no return? The hidden impact of antibacterial resistance in respiratory tract infection. Introduction.
Craig
W A
WA
William S. Middleton Memorial VA Hospital, Madison, Wisconsin, USA. william.craig@med.va.gov
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D018942:Macrolides; D001936:Moraxella catarrhalis; D016870:Neisseriaceae Infections / Q000188:drug therapy; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D018942:Macrolides